Look Past The Setbacks And Give CRISPR Therapeutics AG (NASDAQ: CRSP) Another Chance

CRISPR Therapeutics AG (NASDAQ:CRSP) currently has a daily average trading volume of 1.31M but it saw 1144074 shares traded in last market. With a market cap of 5.07B USD, the company’s current market price of $59.72 came rising about 2.48 while comparing to the previous closing price of $58.28. In past 52 weeks, the stock remained buoying in the range of price level as high as $91.10 and as low as $37.55.

Taking a look at 20-day trading activity of CRISPR Therapeutics AG (CRSP) gives us an average price of $55.39, while its current price level is -34.45% below from 52-week high level whereas it is 59.04% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $58.03 while that of 200 days or SMA-200 reads an average of $59.75. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.68% during that period while stretching the period over a month that increases to 4.81%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 59.90 which implies that the stock is in neutral territory.

TD Cowen downgraded its recommendation for the stock as a “Underperform” from “Market Perform” on December 11, 2023 while assigning a price target of $30.

Over the week, CRSP’s stock price is moving 10.90% up while it is 4.66% when we observe its performance for the past one month. Year-to-date it is -4.60% down and over the past year, the stock is showing a downside performance of -8.12%.

The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.98 beat the consensus estimate of -2.12 for the same. In next quarter, company is expected to be making quarterly sales of $17.62M as analysts are expecting the sales for current fiscal year at $63.18M and seeing the company making $334.63M in sales next year. Moreover, analysts are in estimates of $4.09M for current-quarter revenue.

Currently, CRISPR Therapeutics AG’s total number of outstanding shares is 84.92M. Company’s return on investment (ROI) stands at -9.43% and return on equity (ROE) at -11.03%. Stock’s beta reads 1.70. Stock has a price to book (P/B) ratio of 2.43 while price to sale or P/S ratio amounts to 18.66. Its return on asset (ROA) is -9.27% on average.